- Home
- PAGP vs MRUS Comparison
PAGP vs MRUS Comparison
Compare PAGP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAGP
- MRUS
- Stock Information
- Founded
- PAGP 2013
- MRUS 2003
- Country
- PAGP United States
- MRUS Netherlands
- Employees
- PAGP N/A
- MRUS N/A
- Industry
- PAGP Natural Gas Distribution
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- PAGP Energy
- MRUS Health Care
- Exchange
- PAGP Nasdaq
- MRUS Nasdaq
- Market Cap
- PAGP 3.6B
- MRUS 4.1B
- IPO Year
- PAGP 2013
- MRUS 2016
- Fundamental
- Price
- PAGP $19.23
- MRUS $52.66
- Analyst Decision
- PAGP Hold
- MRUS Strong Buy
- Analyst Count
- PAGP 8
- MRUS 12
- Target Price
- PAGP $20.71
- MRUS $87.92
- AVG Volume (30 Days)
- PAGP 1.8M
- MRUS 1.1M
- Earning Date
- PAGP 08-01-2025
- MRUS 07-31-2025
- Dividend Yield
- PAGP 7.82%
- MRUS N/A
- EPS Growth
- PAGP N/A
- MRUS N/A
- EPS
- PAGP 0.74
- MRUS N/A
- Revenue
- PAGP $50,089,000,000.00
- MRUS $54,732,000.00
- Revenue This Year
- PAGP N/A
- MRUS $75.57
- Revenue Next Year
- PAGP $29.75
- MRUS $31.84
- P/E Ratio
- PAGP $26.43
- MRUS N/A
- Revenue Growth
- PAGP 3.56
- MRUS 42.77
- 52 Week Low
- PAGP $16.61
- MRUS $33.19
- 52 Week High
- PAGP $22.31
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- PAGP 53.47
- MRUS 51.16
- Support Level
- PAGP $18.80
- MRUS $52.53
- Resistance Level
- PAGP $19.50
- MRUS $54.00
- Average True Range (ATR)
- PAGP 0.42
- MRUS 1.69
- MACD
- PAGP 0.01
- MRUS -0.62
- Stochastic Oscillator
- PAGP 32.75
- MRUS 15.89
About PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.